ReviewCancer journal (Sudbury, Mass.)
Microbiome in reflux disorders and esophageal adenocarcinoma.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Diagnosis and treatment of patients with gastroesophageal reflux disease - a systematic review of cost-effectiveness and economic burden.BMC health services research · 2024Pooled it
- Article
- Preliminary insights into gut microbiome shifts as screening proxy for MASLD disease progression.Scientific reports · 2026Article
- The Potential Role ofMicroorganisms · 2025Review
- The role of the esophageal and intestinal microbiome in gastroesophageal reflux disease: past, present, and future.Frontiers in immunology · 2025Review
- The interplay between alterations in esophageal microbiota associated with Th17 immune response and impaired LC20 phosphorylation in achalasia.Journal of gastroenterology · 2024Article
- Respiratory infectious burden in a cohort of antibody deficiency patients treated with immunoglobulin replacement therapy: The impact of lung pathology and gastroesophageal reflux disease.The journal of allergy and clinical immunology. Global · 2023Article
- Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease.Frontiers in cellular and infection microbiology · 2023Article
- Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases.The FEBS journal · 2022Review
- Host-Microbiota Interactions in the Esophagus During Homeostasis and Allergic Inflammation.Gastroenterology · 2022Article
- Role of Microbial Infection-Induced Inflammation in the Development of Gastrointestinal Cancers.Medicines (Basel, Switzerland) · 2021Review
- Impact of Environmental and Pharmacologic Changes on the Upper Gastrointestinal Microbiome.Biomedicines · 2021Review
- Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: A paradigm shift from acid to bacteria?World journal of gastroenterology · 2021Review
- Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- The Life-Long Role of Nutrition on the Gut Microbiome and Gastrointestinal Disease.Gastroenterology clinics of North America · 2021Review
- Novel Ex Vivo Model to Examine the Mechanism and Relationship of Esophageal Microbiota and Disease.Biomedicines · 2021Article
- Microbiota Detection Patterns Correlate With Presence and Severity of Barrett's Esophagus.Frontiers in cellular and infection microbiology · 2021Article
- Human Microbiota in Esophageal Adenocarcinoma: Pathogenesis, Diagnosis, Prognosis and Therapeutic Implications.Frontiers in microbiology · 2021Review
- Gut Microbiota for Esophageal Cancer: Role in Carcinogenesis and Clinical Implications.Frontiers in oncology · 2021Review
- Alterations of bacterial communities of vocal cord mucous membrane increases the risk for glottic laryngeal squamous cell carcinoma.Journal of Cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The incidence of esophageal adenocarcinoma has increased dramatically in the United States and Europe since the 1970s without apparent cause. Although specific host factors can affect risk of disease, such a rapid increase in incidence must be predominantly environmental. In the stomach, infection with Helicobacter pylori has been linked to chronic atrophic gastritis, an inflammatory precursor of gastric adenocarcinoma. However, the role of H. pylori in the development of esophageal adenocarcinoma is not well established. Meanwhile, several studies have established that a complex microbiome in the distal esophagus might play a more direct role. Transformation of the microbiome in precursor states to esophageal adenocarcinoma-reflux esophagitis and Barrett metaplasia-from a predominance of gram-positive bacteria to mostly gram-negative bacteria raises the possibility that dysbiosis is contributing to pathogenesis. However, knowledge of the microbiome in esophageal adenocarcinoma itself is lacking. Microbiome studies open a new avenue to the understanding of the etiology and pathogenesis of reflux disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.